Zemaitatis v. Innovasive Devices, Inc.

90 F. Supp. 2d 631, 90 F. Supp. 631, 2000 U.S. Dist. LEXIS 4057, 2000 WL 329206
CourtDistrict Court, E.D. Pennsylvania
DecidedMarch 17, 2000
DocketCivil Action 98-1221
StatusPublished

This text of 90 F. Supp. 2d 631 (Zemaitatis v. Innovasive Devices, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Zemaitatis v. Innovasive Devices, Inc., 90 F. Supp. 2d 631, 90 F. Supp. 631, 2000 U.S. Dist. LEXIS 4057, 2000 WL 329206 (E.D. Pa. 2000).

Opinion

MEMORANDUM AND ORDER

SHAPIRO, Senior District Judge.

A jury found by a preponderance of the evidence that a defectively designed product of defendant Innovasive Devices, Inc. (“Innovasive”) was a substantial factor in causing harm suffered by plaintiff, Scott Zemaitatis. The verdict awarded Zemaita-tis was $47,000 in medical expenses and $250,000 for pain and suffering. Innova-sive, moving for judgment as a matter of law, a new trial, and/or remittitur of the pain and suffering award, argues that: 1) it was error to allow plaintiffs expert witness to testify; 2) it was error to preclude defendant’s expert witness from testifying about FDA approval data; 3) the verdict was against the weight of the evidence; and 4) a remittitur of damages should be granted. Zemaitatis moved to mold the verdict and for delay damages under Pennsylvania Rule of Civil Procedure 238. BACKGROUND

Plaintiff Scott Zemaitatis (“Zemaitatis”) was a varsity swimmer and soccer player at Eastern Regional High School in Voo-rhees, New Jersey, when his left shoulder became dislocated in May, 1995; there was a spontaneous reduction. This happened again four or five times in the following months. In August, 1995, Zemaitatis consulted Dr. Joseph P. Iannotti (“Dr.Iannot-ti”) about his shoulder; at Zemaitatis’s request, Dr. Iannotti did not operate on plaintiff to correct the condition until March 7,1996.

The operative procedure involved placing suture anchors in plaintiffs shoulder. The suture anchors, designed and manufactured by Innovasive, consisted of a collar and a pin inserted into the collar to expand outward against the bone surface. Suture material was pre-loaded into an eye at the top of the pin. Defendant’s delivery system also included a drill with a prefixed depth, drill guide, and gun trigger. Dr. Iannotti drilled holes, inserted three collars, pushed in the pins, and tied sutures to the eyes of the pins. The ligaments around the shoulder were then tied in place.

Zemaitatis followed a rehabilitation program after the operation, but noticed a clicking noise and felt some discomfort in his shoulder. Dr. Iannotti recommended corrective surgery; at the second operation two months later, Dr. Iannotti found the pins in all three anchors protruding above the level of the bone; he corrected this by filing each pin to bone level.

After the second surgery, Zemaitatis claimed to suffer increasing shoulder pain affecting his ability to play soccer and swim. He insisted on a third surgery in *633 June, 1997; it revealed degenerative changes in the articular cartilage around his shoulder bone.

DISCUSSION

I. Plaintiffs expert witness

In order to establish defectiveness of the suture anchor and causation, plaintiff offered the expert testimony of Dr. Steven Batterman. The court held two hearings in accordance with Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), to consider Dr. Batterman’s proposed testimony and arguments of counsel. 1 Under DaubeH, the trial court makes a determination whether: 1) the proposed witness is qualified as an expert, 2) the expert employs a reliable reasoning or methodology; and 3) the reasoning or methodology is relevant. See Daubert, 509 U.S. at 592-93, 113 S.Ct. 2786. The test is flexible and should focus on reasoning and methods not conclusions. See Daubert, 509 U.S. at 594-95, 113 S.Ct. 2786. It was ordered that Dr. Batterman could testify that: 1) defendant’s suture anchor system was defectively designed because it was loaded from the front rather than the rear; and 2) the engineering of defendant’s product caused plaintiff’s injury. Dr. Batterman was precluded from testifying that defendant’s system was defective for any other reason, or giving medical opinions.

Innovasive argues it was error to allow Dr. Batterman to testify at all because his testimony lacked a scientific basis. Innovasive also argues that Dr. Batterman lacked specific qualifications as to education, training or experience necessary for him to render an opinion regarding the design of the suture anchors. It is true that Dr. Batterman is a jack-of-all-trades expert, but the court was satisfied he possessed sufficient qualifications to testify in the limited areas permitted. The court determined that Dr. Batterman’s opinion regarding loading of the suture anchors was admissible because it had sufficient scientific basis to aid the jury in reaching an accurate result. See In re Paoli Railroad Yard PCB Litigation, 35 F.3d 717, 746 (3d Cir.1994). These findings satisfied the Daubert requirements; no new evidence or argument has been presented post-trial.

II. Innovasive’s expert witness

Innovasive argues that its expert, Steven Kurz, should have been allowed to testify to Food and Drug Administration data (“FDA data”) he reviewed to assess the safety of Innovasive’s suture anchor. 2 The court denied Innovasive’s motion in limine to allow testimony regarding the FDA data because it was irrelevant and unduly prejudicial. See Fed.R.Evid. 402, 403.

Innovasive obtained FDA approval of the suture anchor by asserting it was “substantially equivalent” to other devices already on the market. See 21 U.S.C. § 360e(b)(l)(B). Devices on the market have not all been rigorously tested by the FDA; most devices currently on the market have not received detailed FDA review. See Medtronic, Inc. v. Lohr, 518 U.S. 470, 477-78, 116 S.Ct. 2240, 135 L.Ed.2d 700 (1996). The suture anchor at issue was never subjected to FDA de novo review. Cf. Medtronic, Inc. v. Lohr, 518 U.S. at 479, 116 S.Ct. 2240 (“in contrast to the 1,200 hours necessary to complete a [de novo FDA review], the [‘substantial equivalence’ review] is completed in an average of only 20 hours.”); Orthopedic Bone Screw Prods. Liab. Litig., 193 F.3d 781, 786 (3d Cir.1999) (if a device obtains FDA approval because of its substantial equivalence, it may be introduced into *634 commerce without pre-market approval based on safety and efficacy data from independent investigation). Testimony of FDA approval was likely to lead the jury to believe the FDA conducted substantial testing of the suture anchors; it would give the product an unearned stamp of approval. The court determined the evidence, if admitted, would unduly prejudice the jury.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
90 F. Supp. 2d 631, 90 F. Supp. 631, 2000 U.S. Dist. LEXIS 4057, 2000 WL 329206, Counsel Stack Legal Research, https://law.counselstack.com/opinion/zemaitatis-v-innovasive-devices-inc-paed-2000.